Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 569 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Potassium Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers

NCT01325051
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Raltegravir
Drug
Lead sponsor
Angela Kashuba, PharmD
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 24, 2026, 9:19 PM EDT
Recruiting Phase 2 Interventional

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

NCT05501756
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Alemtuzumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fluid Loading Countermeasures

NCT06467812
View directory record Official record
Conditions
Healthy
Interventions
Salt Tablets, Electrolyte Solution
Dietary Supplement
Lead sponsor
National Aeronautics and Space Administration (NASA)
Federal
Eligibility
25 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 4 Interventional

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

NCT00752037
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir and raltegravir
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Prepared Meals to Prime and Perpetuate Reduced Dietary Sodium Intake in Hemodialysis

NCT03990311
View directory record Official record
Conditions
Hypertension in Dialysis Patients, Fluid Overload in Dialysis Patients
Interventions
Sodium Restricted Meals, Control
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions

NCT01216852
View directory record Official record
Conditions
Hypertension
Interventions
Losartan Potassium
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 4 Interventional Results available

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

NCT03183778
View directory record Official record
Conditions
Chronic Kidney Diseases, Hyperkalemia
Interventions
Patiromer, Research Diet Menu
Drug · Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 24, 2026, 9:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

NCT05353322
View directory record Official record
Conditions
Sedentary Behavior, Cardiometabolic Risk Factors, Blood Pressure, Glucose
Interventions
Sedentary Break (Walking) Condition, Sitting (Control) Condition, Controlled Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 4 Interventional

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

NCT00185094
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions
Olmesartan medoxomil, Losartan potassium, Atenolol
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2005 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck

NCT01275183
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
raltegravir and cisplatin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 4 Interventional Results available

Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis

NCT03176966
View directory record Official record
Conditions
Muscle Cramp, Cirrhosis
Interventions
Vitamin E, Ropinirole, Muscle cramp survey
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)

NCT02568722
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Standard RRT initiation, Accelerated RRT initiation
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
3,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • Gainesville, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 4 Interventional Results available

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

NCT04519164
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions
Eplerenone, Chlorthalidone with potassium chloride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Recruiting Phase 2 Interventional

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

NCT05766839
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
0 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 24, 2026, 9:19 PM EDT
Terminated Phase 4 Interventional Results available

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A

NCT03519347
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Potassium Removal Maximization, Potassium Gradient Minimization, Alkalosis Avoidance, Acidosis avoidance, Point of Care Testing, Cardiac Monitor
Other · Diagnostic Test · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 24, 2026, 9:19 PM EDT
Withdrawn No phase listed Observational

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

NCT07493798
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Potassium estimation algorithm
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Raltegravir Kaletra Pharmacokinetics

NCT00564772
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir, lopinavir, ritonavir
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

NCT01780831
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 24, 2026, 9:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Implementation of Asthma Community Home and School Management Program (Asthma CHAMPS)

NCT05814510
View directory record Official record
Conditions
Asthma in Children
Interventions
Asthma CHAMPS full program, Asthma CHAMPS Wait List Control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 24, 2026, 9:19 PM EDT
Not yet recruiting Early Phase 1 Interventional

Predictors & Mechanisms of Adolescent PTSD

NCT07537764
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Trauma Exposure
Interventions
Repeated imaginal exposure: Script Driven Imagery (SDI) task
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
14 Years to 18 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists

NCT04903717
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Best Practice Alert
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 24, 2026, 9:19 PM EDT